In a retrospective analysis of 58 NSCLC patients treated with PD-(L)1 inhibitors, responses were observed in only 4% of ALK-positive or EGFR-mutant tumors versus 23% of ALK-negative/unknown and EGFR wild-type tumors [59]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.